{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:24:13Z","timestamp":1793107453757,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.yrtph.2009.10.006","type":"journal-article","created":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T09:11:31Z","timestamp":1257066691000},"page":"343-351","source":"Crossref","is-referenced-by-count":105,"title":["Human health risk assessment of carbamazepine in surface waters of North America and Europe"],"prefix":"10.1016","volume":"56","author":[{"given":"Virginia L.","family":"Cunningham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Perino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent J.","family":"D\u2019Aco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Bechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2009.10.006_bib1","unstructured":"ACD. Advanced Chemistry Development, Version 9.0. ACD\/Labs."},{"key":"10.1016\/j.yrtph.2009.10.006_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0021-9673(00)01187-0","article-title":"Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry","volume":"910","author":"Ahrer","year":"2001","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.yrtph.2009.10.006_bib3","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3109\/00498258909043191","article-title":"Enzymic synthesis of two glucuronides of the hydroxyisoxazole GABA-agonist, THIP, and the in vivo glucuronidation of THIP in rats","volume":"19","author":"Anderson","year":"1989","journal-title":"Xenobiotica"},{"key":"10.1016\/j.yrtph.2009.10.006_bib4","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1021\/es034430b","article-title":"Screening analysis of human pharmaceutical compounds in U.S. surface waters","volume":"38","author":"Anderson","year":"2004","journal-title":"Environmental Science & Technology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib5","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/S0043-1354(01)00500-0","article-title":"Carbamazepine in water: persistence in the environment, ozonation treatment and preliminary assessment on algal toxicity","volume":"36","author":"Andreozzi","year":"2002","journal-title":"Water Research"},{"key":"10.1016\/j.yrtph.2009.10.006_bib6","unstructured":"Apotex Corporation, 2002. Carbamazepine Tablets USP. Package Insert with Prescribing Information."},{"key":"10.1016\/j.yrtph.2009.10.006_bib7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0021-9258(19)77402-X","article-title":"Enzymatic synthesis of N-glucosyluronic acid conjugates","volume":"232","author":"Axelrod","year":"1961","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.yrtph.2009.10.006_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jhazmat.2005.03.012","article-title":"Occurrence and fate of pharmaceutically active compounds in the environment, a case study: H\u00f6je River in Sweden","volume":"122","author":"Bendz","year":"2005","journal-title":"Journal of Hazardous Materials"},{"key":"10.1016\/j.yrtph.2009.10.006_bib9","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1021\/es0629965","article-title":"Distributions of pharmaceuticals in an urban estuary during both dry- and wet-weather conditions","volume":"41","author":"Benotti","year":"2007","journal-title":"Environmental Science & Technology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.yrtph.2008.01.014","article-title":"Human health risk assessments for three neuropharmaceutical compounds in surface waters","volume":"50","author":"Bercu","year":"2008","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/rtph.1998.1253","article-title":"Pharmaceuticals in the environment \u2013 a human risk?","volume":"28","author":"Christensen","year":"1998","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.watres.2003.10.058","article-title":"Carbamazepine as a possible anthropogenic marker in the aquatic environment: investigations on the behaviour of Carbamazepine in wastewater treatment and during groundwater infiltration","volume":"38","author":"Clara","year":"2004","journal-title":"Water Research"},{"key":"10.1016\/j.yrtph.2009.10.006_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.scitotenv.2005.01.036","article-title":"Comparing pharmaceutical and pesticide loads into a small Mediterranean river","volume":"349","author":"Comoretto","year":"2005","journal-title":"Science of the Total Environment"},{"key":"10.1016\/j.yrtph.2009.10.006_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.yrtph.2008.10.006","article-title":"Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment","volume":"53","author":"Cunningham","year":"2009","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib15","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1021\/es063017b","article-title":"Effects of human pharmaceuticals on aquatic life: next steps","volume":"40","author":"Cunningham","year":"2006","journal-title":"Environmental Science & Technology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib16","unstructured":"Daylight, 2005. Daylight Version 4.9, Release Date 04\/08\/05. Daylight Chemical Information Systems, Inc."},{"key":"10.1016\/j.yrtph.2009.10.006_bib17","first-page":"271","article-title":"Carbamazepine","volume":"vol. 138","author":"Dickinson","year":"1999"},{"key":"10.1016\/j.yrtph.2009.10.006_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.watres.2004.09.016","article-title":"Photocatalytic degradation of carbamazepine, clofibric acid and iomeprol with P25 and Hombikat UV100 in the presence of natural organic matter (NOM) and other organic water constituents","volume":"39","author":"Doll","year":"2005","journal-title":"Water Research"},{"key":"10.1016\/j.yrtph.2009.10.006_bib19","unstructured":"European Commission, 2003. Technical Guidance Document on Risk Assessment, Part II, European Communities, Table 16, p. 20. Available from: <http:\/\/ecb.jrc.it\/home.php?CONTENU=\/Technical-Guidance-Document\/sommaire.php>."},{"key":"10.1016\/j.yrtph.2009.10.006_bib20","series-title":"Epileptic Seizure\u2013Behaviour\u2013Pain","first-page":"127","article-title":"The biotransformation of carbamazepine","author":"Faigle","year":"1976"},{"key":"10.1016\/j.yrtph.2009.10.006_bib21","series-title":"Epileptic Seizure\u2013Behaviour\u2013Pain","first-page":"159","article-title":"Pharmacokinetic data of carbamazepine and its major metabolites in man","author":"Faigle","year":"1976"},{"key":"10.1016\/j.yrtph.2009.10.006_bib22","series-title":"Antiepileptic Drugs","first-page":"483","article-title":"Carbamazepine biotransformation","author":"Faigle","year":"1982"},{"key":"10.1016\/j.yrtph.2009.10.006_bib23","series-title":"Antiepileptic Drugs","first-page":"499","article-title":"Carbamazepine chemistry and biotransformation","author":"Faigle","year":"1995"},{"key":"10.1016\/j.yrtph.2009.10.006_bib24","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/S0045-6535(97)00048-9","article-title":"Development of a Geography-referenced Regional Exposure Assessment Tool for European Rivers \u2013 GREAT-ER. Contribution to GREAT-ER # 1","volume":"34","author":"Feijtel","year":"1997","journal-title":"Chemosphere"},{"key":"10.1016\/j.yrtph.2009.10.006_bib25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.scitotenv.2008.02.021","article-title":"A national reconnaissance for pharmaceuticals and other organic wastewater contaminants in the United States \u2013 II. Untreated drinking water sources","volume":"402","author":"Focazio","year":"2008","journal-title":"Science of the Total Environment"},{"issue":"252","key":"10.1016\/j.yrtph.2009.10.006_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0048-9697(00)00392-2","article-title":"The use of measured boron concentration data from the GREAT-ER UK validation study (1996\u20131998) to generate predicted regional boron concentrations","volume":"251","author":"Fox","year":"2000","journal-title":"The Science of the Total Environment"},{"key":"10.1016\/j.yrtph.2009.10.006_bib27","series-title":"Epileptic Seizure\u2013Behaviour\u2013Pain","first-page":"58","article-title":"The chemistry of carbamazepine","author":"Gagneux","year":"1976"},{"key":"10.1016\/j.yrtph.2009.10.006_bib28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00216-005-0199-y","article-title":"Determination of pharmaceuticals in environmental waters by liquid chromatography\/electrospray ionization\/tandem mass spectrometry","volume":"384","author":"Hao","year":"2006","journal-title":"Analytical and Bioanalytical Chemistry"},{"key":"10.1016\/j.yrtph.2009.10.006_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0378-4274(02)00041-3","article-title":"Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of current research data","volume":"131","author":"Heberer","year":"2002","journal-title":"Toxicology Letters"},{"key":"10.1016\/j.yrtph.2009.10.006_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jhazmat.2005.03.007","article-title":"Contribution of effluents from hospitals and private households to the total loads of diclofenac and carbamazepine in municipal sewage effluents \u2013 modeling versus measurements","volume":"122","author":"Heberer","year":"2005","journal-title":"Journal of Hazardous Materials"},{"key":"10.1016\/j.yrtph.2009.10.006_bib31","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1021\/es025896h","article-title":"Oxidation of pharmaceuticals during ozonation and advanced oxidation processes","volume":"37","author":"Huber","year":"2003","journal-title":"Environmental Science & Technology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib32","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1021\/es061740w","article-title":"Simultaneous determination of psychoactive drugs and their metabolites in aqueous matrices by liquid chromatography mass spectrometry","volume":"40","author":"Hummel","year":"2006","journal-title":"Environmental Science & Technology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib33","unstructured":"IMS Health, Inc., 2005. IMS Midas Quantum Year End 2004."},{"key":"10.1016\/j.yrtph.2009.10.006_bib34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/10408440490464697","article-title":"Potential ecological and human health risks associated with the presence of pharmaceutically active compounds in the aquatic environment","volume":"34","author":"Jones","year":"2004","journal-title":"Critical Reviews in Toxicology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib35","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1016\/j.watres.2005.05.031","article-title":"Removal of pharmaceuticals and fragrances in biological wastewater treatment","volume":"39","author":"Joss","year":"2005","journal-title":"Water Research"},{"key":"10.1016\/j.yrtph.2009.10.006_bib36","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1021\/es011055j","article-title":"Pharmaceuticals, hormones, and other organic wastewater contaminant in U.S. streams, 1999\u20132000: a national reconnaissance","volume":"36","author":"Kolpin","year":"2002","journal-title":"Environmental Science & Technology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib37","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1897\/03-421","article-title":"Aquatic persistence of eight pharmaceuticals in a microcosm study","volume":"23","author":"Lam","year":"2004","journal-title":"Environmental Toxicology and Chemistry"},{"key":"10.1016\/j.yrtph.2009.10.006_bib38","series-title":"EU Wide Monitoring Survey of Polar Persistent Pollutants in European River Waters","author":"Loos","year":"2008"},{"key":"10.1016\/j.yrtph.2009.10.006_bib39","series-title":"Antiepileptic Drugs","first-page":"227","article-title":"Carbamazepine mechanisms of action","author":"McDonald","year":"2002"},{"key":"10.1016\/j.yrtph.2009.10.006_bib40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/etc.5620180412","article-title":"Improved method for estimating bioconcentration\/bioaccumulation factor from octanol\/water partition coefficient","volume":"18","author":"Meylan","year":"1999","journal-title":"Environmental Toxicology and Chemistry"},{"key":"10.1016\/j.yrtph.2009.10.006_bib41","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1021\/es050261e","article-title":"Carbamazepine and its metabolites in wastewater and in biosolids in a municipal wastewater treatment plant","volume":"39","author":"Miao","year":"2005","journal-title":"Environmental Science & Technology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib42","unstructured":"Novartis, 1996. Tegretol-Xr (Carbamazepine Extended Release Tablets). NDA #020234. Available from: <http:\/\/www.fda.gov\/cder\/foi\/nda\/96\/020234_complete_Approval_pkg.pdf>."},{"key":"10.1016\/j.yrtph.2009.10.006_bib43","unstructured":"Novartis, 2007. Tegretol\u00ae-XR (Carbamazepine Extended-Release Tablets) 100mg, 200mg, 400mg Prescribing Information, vol. 2007, p. 1. Available from: <http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/tegretol.pdf> (accessed 12.03.07)."},{"key":"10.1016\/j.yrtph.2009.10.006_bib44","unstructured":"Novartis Pharmaceuticals Corporation, 2006. Tegretol\u00ae and Tegretol\u00ae-XR. Prescribing Information."},{"key":"10.1016\/j.yrtph.2009.10.006_bib45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2166\/wst.2004.0335","article-title":"Removal of selected non-steroidal anti-inflammatory drugs (NSAIDs), gemfibrozil, carbamazepine, b-blockers, trimethoprim and triclosan in conventional wastewater treatment plants in five EU countries and their discharge to the aquatic environment","volume":"50","author":"Pax\u00e9us","year":"2004","journal-title":"Water Science and Technology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib46","unstructured":"Physicians\u2019 Desk Reference, 2004. 58th Ed. Thomson PDR, Montvale, NJ."},{"key":"10.1016\/j.yrtph.2009.10.006_bib47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/etc.5620070204","article-title":"Prediction of consumer product chemical concentrations as a function of publicly owned treatment works treatment type and river dilution","volume":"7","author":"Rapaport","year":"1988","journal-title":"Environmental Toxicology and Chemistry"},{"key":"10.1016\/j.yrtph.2009.10.006_bib48","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/10807030290879899","article-title":"A human health risk assessment of pharmaceuticals in the aquatic environment","volume":"8","author":"Schulman","year":"2002","journal-title":"Human and Ecological Risk Assessment"},{"key":"10.1016\/j.yrtph.2009.10.006_bib49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.yrtph.2005.05.005","article-title":"Human pharmaceuticals in U.S. surface water: a human health risk assessment","volume":"42","author":"Schwab","year":"2005","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib50","unstructured":"Shire, 2006. Carbatrol\u00ae. Prescribing Information."},{"key":"10.1016\/j.yrtph.2009.10.006_bib51","first-page":"240","article-title":"Carbamazepine chemistry, biotransformation, and pharmacokinetics","volume":"vol. 5","author":"Spina","year":"2002"},{"key":"10.1016\/j.yrtph.2009.10.006_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.scitotenv.2004.03.015","article-title":"Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking water treatment plant","volume":"329","author":"Stackelberg","year":"2004","journal-title":"Science of the Total Environment"},{"key":"10.1016\/j.yrtph.2009.10.006_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.scitotenv.2007.01.095","article-title":"Efficiency of conventional drinking-water-treatment processes in removal of pharmaceuticals and other organic compounds","volume":"377","author":"Stackelberg","year":"2007","journal-title":"Science of the Total Environment"},{"key":"10.1016\/j.yrtph.2009.10.006_bib54","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00007691-199612000-00006","article-title":"Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication","volume":"18","author":"Sviranov","year":"1996","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.yrtph.2009.10.006_bib55","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/S0043-1354(98)00099-2","article-title":"Occurrence of drugs in German sewage treatment plants and rivers","volume":"32","author":"Ternes","year":"1998","journal-title":"Water Research"},{"key":"10.1016\/j.yrtph.2009.10.006_bib56","series-title":"Pharmaceuticals and Personal Care Products in the Environment: Scientific and Regulatory Issues","first-page":"23","article-title":"Pharmaceuticals and metabolites as contaminants of the aquatic environment","author":"Ternes","year":"2001"},{"key":"10.1016\/j.yrtph.2009.10.006_bib57","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1021\/es015757k","article-title":"Removal of pharmaceuticals during drinking water treatment","volume":"36","author":"Ternes","year":"2002","journal-title":"Environmental Science & Technology"},{"key":"10.1016\/j.yrtph.2009.10.006_bib58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0021-9673(01)01266-3","article-title":"Pharmaceuticals in groundwaters: analytical methods and results of a monitoring program in Baden-Wurttemberg, Germany","volume":"938","author":"Ternes","year":"2001","journal-title":"Journal Chromatography A"},{"key":"10.1016\/j.yrtph.2009.10.006_bib59","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/S0043-1354(02)00570-5","article-title":"Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater?","volume":"37","author":"Ternes","year":"2003","journal-title":"Water Research"},{"key":"10.1016\/j.yrtph.2009.10.006_bib60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.chroma.2007.10.105","article-title":"Multi-residue analysis of pharmaceutical compounds in aqueous samples","volume":"1177","author":"Togola","year":"2008","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.yrtph.2009.10.006_bib61","unstructured":"U.S. EPA, 1992. Guidelines for Exposure Assessment. EPA\/600\/Z-92\/001, p. 81."},{"key":"10.1016\/j.yrtph.2009.10.006_bib62","unstructured":"U.S. EPA, 2000. Methodology for Deriving Ambient Water Quality Criteria for the Protection of Human Health. Office of Water, Office of Science and Technology. EPA 822 B 00 004, October 2000."},{"key":"10.1016\/j.yrtph.2009.10.006_bib63","unstructured":"U.S. EPA, 2005. Exposure and Fate Assessment Screening Tool (E-FAST), Version 2.0, October 2005, pp. 3\u201329. Available from: <http:\/\/www.epa.gov\/oppt\/exposure>."},{"key":"10.1016\/j.yrtph.2009.10.006_bib64","unstructured":"U.S. FDA, 1999. Benefit vs. risk: how CDER approves new drugs. In: From Test Tube to Patient: Improving Health through Human Drugs. U.S. Food and Drug Administration Center for Drug Evaluation and Research Special Report, pp. 33\u201340."},{"key":"10.1016\/j.yrtph.2009.10.006_bib65","unstructured":"United States Pharmacopeia, 2005. Carbamazepine. Material Safety Data Sheet."},{"key":"10.1016\/j.yrtph.2009.10.006_bib66","unstructured":"Validus, 2007. Equetro\u2122. Prescribing Information."},{"key":"10.1016\/j.yrtph.2009.10.006_bib67","series-title":"Science for Assessing the Impacts of Human Pharmaceuticals on Aquatic Ecosystems","first-page":"71","article-title":"Environmental exposure modeling and monitoring of human pharmaceuticals in the environment","author":"Versteeg","year":"2005"},{"key":"10.1016\/j.yrtph.2009.10.006_bib68","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0378-4274(03)00071-7","article-title":"Indirect exposure to pharmaceuticals via drinking water","volume":"142","author":"Webb","year":"2003","journal-title":"Toxicology Letters"},{"key":"10.1016\/j.yrtph.2009.10.006_bib69","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/jps.2600720806","article-title":"Steady-state determination of the contribution of lung metabolism to the total body clearance of drugs: application to carbamazepine","volume":"72","author":"Wedlund","year":"1983","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.yrtph.2009.10.006_bib70","unstructured":"World Health Organization, 1999. International Programme for Chemical Safety. INCHEM. Carbamazepine."},{"key":"10.1016\/j.yrtph.2009.10.006_bib71","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.chroma.2007.02.047","article-title":"Optimizing gas chromatographic\u2013mass spectrometric analysis of selected pharmaceuticals and endocrine-disrupting substances in water using factorial experimental design","volume":"1148","author":"Yu","year":"2007","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.yrtph.2009.10.006_bib72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.aca.2007.11.024","article-title":"Analysis of emerging contaminants in sewage effluent and river water: comparison between spot and passive sampling","volume":"608","author":"Zhang","year":"2008","journal-title":"Analytica Chimica Acta"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230009002207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230009002207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T06:28:13Z","timestamp":1634106493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230009002207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0273230009002207"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2009.10.006","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}